Guillain-Barré syndrome is a rare complication in the setting of hematopoietic stem cell transplantation. We report three children with T cell lymphoma/leukemia in whom this syndrome developed soon after they received unrelated donor transplants. The rapid onset of symptoms raises the concern that the bone marrow transplant conditioning regimen (ie, total body irradiation, cyclophosphamide and cytosine arabinoside) might have precipitated the clinical syndrome of ascending polyneuropathy. Although central nervous system toxicity has been well described with high-dose cytosine arabinoside therapy, peripheral neuropathy of the GuillainBarré type has been reported only infrequently. We review possible factors contributing to the development of this syndrome in these three patients. Bone Marrow Transplantation (2002) 29, 515-517. DOI: 10.1038/sj/bmt/1703412 Keywords: Guillain-Barré syndrome; polyneuropathy; hematopoietic stem cell transplantation Hematopoietic stem cell transplant (HSCT) recipients are at risk for neurologic complications. These neurologic effects may arise from the primary disease for which the patient is undergoing HSCT, from infection that may develop during the HSCT, or as a consequence of other treatment.
Case reports
Case 1 A 16-year-old Caucasian boy was diagnosed as having T cell leukemia with central nervous system disease and was treated with a Pediatric Oncology Group (POG) protocol (POG 9404) that included craniospinal irradiation (1800 cGy). At week 84, he presented with a central nervous system relapse. The patient underwent three-drug reinduction and six consolidation courses of chemotherapy consisting of high-dose cytosine arabinoside (Ara-C) and triple intrathecal chemotherapy (methotrexate, Ara-C, hydrocortisone) alternating with vincristine, prednisone, and 6-mercaptopurine. He was referred to our institution for a 5/6 mismatched unrelated bone marrow donor transplant.
HSCT conditioning therapy was administered according to protocol: Ara-C, 3 g/m 2 every 12 h for six doses on day −8 to day −5; cyclophosphamide, 45 mg/kg for two doses on days −7 and −6, and Mesna; antithymocyte globulin, 30 mg/kg on days −7, −6 and −5; and total body irradiation, 14.0 Gy divided into eight fractions per day beginning on day −4, with boosts to the cranium. For prophylaxis of graft-versus-host disease, the patient received cyclosporine starting on day −2, and the donor bone marrow underwent in vitro T cell depletion. 5 On day −5, rhinorrea was noted and culture and enzyme immunoassay were positive for parainfluenza virus type 1 on nasal wash. Treatment with ribavirin and intravenous immunoglobulin (RespiGam) was initiated, and the respiratory symptoms and findings stabilized. On day +6, the patient complained of lower extremity weakness. Levels of electrolytes and creatine kinase were normal. By day +8, symptoms had progressed and included profound muscle weakness and inability to walk. A computed tomography scan of the head was normal. Cerebrospinal fluid (CSF) examination was notable for absence of white blood cells, normal glucose, and increased protein concentration (Table 1) . CSF cultures and viral polymerase chain reactions were negative. Nerve conduction study and electromyelography were consistent with GBS. The patient received a total dose of immunoglobulin of 2 g/kg. Paralysis worsened, and the patient required mechanical ventilation for respiratory failure and cardiac inotropes for autonomic dysfunction with hypotension. After 4 months of intensive care, no improvement was noted in the neurologic state, and the patient died from multisystem failure. Died 3 months after transplant, of protein 50 mg/dl multisystem failure ALL = acute lymphocytic leukemia; Ara-C = cytosine arabinoside; NA = not available.
Case 2
A 17-year-old white man initially presented with a mediastinal mass and right pleural effusion due to T cell lymphoma. After emergency radiation therapy, the patient was treated according to the POG 9404 protocol. After 7 months on therapy, he experienced seizures and encephalopathy. CSF examination was negative for malignancy and infection, and magnetic resonance imaging (MRI) of the head was normal. At week 55, testicular relapse occurred, for which the patient received high-dose methotrexate, Ara-C, l-asparaginase, and testicular irradiation. Response to treatment was incomplete, and further therapy included ifosfamide (1.8 mg/m 2 per dose × 5 doses), etoposide (100 mg/m 2 per dose × 5 doses), compound 506U78 (Ara-G) (650 mg/m 2 × 5 doses), and pelvic irradiation (2600 cGy). The patient received further chemotherapy with high-dose Ara-C and carboplatin but still had residual disease at the time of transplantation. Intrathecal chemotherapy (methotrexate 15 mg, Ara-C 30 mg, hydrocortisone 15 mg) was administered during this period to prevent central nervous system disease.
The bone marrow transplant conditioning regimen was as described for case 1, except that no cranial boost was given. On day +3, the patient experienced paresthesias of the hands and feet, with subsequent ascending weakness, respiratory failure, and required mechanical ventilation by day +5. CSF examination was unremarkable except for increased protein (Table 1) . CSF culture was negative for bacterial and viral disease. MRI of the head and spinal cord showed no evidence of a mass or focal myelopathy. Respiratory cultures were negative for viral infection. The patient was treated with intravenous immunoglobulin. On day +9, autonomic instability developed (ie, hypothermia, hypotension, arrhythmias), which required multiple use of vasopressors. Despite engraftment, the patient never regained motor function. At 6 weeks after transplantation recurrence of lymphoma led to the patient's death 2 weeks later.
Case 3
An 18-year-old man presented with T cell acute lymphocytic leukemia, with an initial white blood cell count of 252 000/l. He received treatment according to the POG 9404 protocol, including cranial irradiation, 1800 cGy. At week 55 of therapy, central nervous system relapse occurred, and the patient received high-dose Ara-C (500 mg/m 2 ), cyclophosphamide, teniposide, and triple intrathecal chemotherapy.
Unrelated donor HSCT was performed after conditioning therapy as in cases 1 and 2. On day +2, the patient complained of paresthesias in the hands and feet. By day +7, wide-based gait and decreased strength bilaterally in the lower extremities were noted, which progressed by day +11 to an inability to walk or stand. Intravenous immunoglobulin was given. Viral cultures from respiratory secretions were negative. CSF examination was remarkable only for increased protein (Table 1) , and CSF cultures were negative for viral and bacterial infection. Spinal cord MRI showed no abnormalities or mass effect. Nerve conduction velocity and electromyographic findings were consistent with a severe sensorimotor polyneuropathy.
The patient's neurologic status stabilized. Respiration did not require mechanical support. The patient was discharged to a rehabilitation facility 6 weeks after transplant. Two weeks later, he was readmitted because of pericardial tamponade, which required pericardiocentesis and eventually placement of a pericardial window. Pericardial fluid cultures remained negative for infection and malignancy. The patient ultimately died of multisystem failure 3 months after transplantation.
Discussion
GBS is characterized by rapidly evolving limb weakness, loss of deep tendon reflexes, absent or mild sensory deficits, and variable autonomic dysfunction. In the majority of cases, the neuropathy is precipitated by a bacterial or viral illness. Weakness can develop acutely (days) or subacutely (up to 4 weeks), and it reaches a plateau, with eventual resolution of paralysis. The pathogenesis remains incompletely understood, but an aberrant organ-specific immune response has been postulated. 4, 6 GBS has been fatal in up to 4.5% of patients, and approximately 30% of patients require mechanical ventilation. Our three patients exhibited the typical clinical signs and symptoms of GBS, including autonomic dysfunction, abnormal nerve conduction and electromyographic findings, and increased levels of CSF protein.
GBS has previously been reported in the setting of HSCT, usually in association with a viral infection. [7] [8] [9] [10] The onset in our patients was earlier than has previously been noted, and whereas patient 1 had an associated parain-fluenza infection, the other two patients had no evidence of viral infection. Wen et al 10 described seven patients with GBS after HSCT. In six of these, GBS developed 10 days to 12 months after the transplant (mean 3.8 months), and as in our patients, GBS developed within 1 week after highdose Ara-C. Johnson et al 1 described a patient in whom GBS developed in the immediate post-transplant period. However, in our patients, the close temporal relationship between the onset of symptoms and drug administration suggests a possible neurotoxic effect precipitated by the conditioning regimen. Patients 2 and 3 had a total cumulative dose of Ara-C of approximately 20 g/m 2 each (including pretransplant and post-transplant use), which put them at risk for neurotoxicity. Central nervous system toxicity from Ara-C has been associated with persistently high central nervous system levels of its metabolite, uracil arabinoside (Ara-U). 11 Cerebellar dysfunction has been the most frequent neurotoxic event reported, affecting 23% of patients (7/30) who received high-dose Ara-C. 12, 13 Our patient 2 also received compound 506U78, which is a prodrug of Ara-G known to have activity in T cell malignancy. Phase I trials have reported weakness, confusion and coma as drugrelated toxicity. One child experienced ascending paralysis and coma after 10 days of drug administration.
14 A number of adults treated in various trials with compound 506U78 have had GBS-type paralysis, 15 and this agent may have had an additive neurotoxic effect in relation to the cumulative doses of Ara-C.
Other factors may have contributed to the observed devastating neurotoxicity, including cranial irradiation and the use of high-dose methotrexate (as in case 2). Dunton et al 16 reported two cases of progressive ascending paralysis after administration of intrathecal and intravenous Ara-C. Autopsy in one of these patients showed spinal cord demyelination characteristic of Ara-C neurotoxicity. 16 However, none of our patients received intrathecal therapy during treatment with high-dose Ara-C. As in the cases of Dunton et al, two of our patients received craniospinal irradiation, which could have been another factor precipitating the observed neurologic sequelae. To our knowledge, no cases of cyclosporine-associated ascending paralysis have been reported. In all three of our patients who received cyclosporine for graft-versus-host prophylaxis, drug levels were within the therapeutic range. Cyclosporine neurotoxicity is characterized by tremors, dysesthesias, seizures, altered mental status, cortical blindness, encephalopathy, and coma. None of our patients had these symptoms, and so we can exclude cyclosporine as a possible neurotoxic factor.
Our cases, in addition to the case reported by Johnson et al, 1 should alert physicians to this potential complication in the setting of intensive chemotherapy treatment before HSCT and the use of certain drugs, including high-dose Ara-C, that can potentiate or precipitate neurologic complications such as GBS. Because of the development of this Bone Marrow Transplantation complication in these three patients, we are now omitting Ara-C in the conditioning regimen for patients with T cell lymphoma or leukemia.
